2009至2019年主要期刊发表的ARDS与脓毒症试验入组情况的系统评价与Meta分析
该研究系统检索Pubmed,纳入2009至2019年间发表于7种最高影响因子综合医学期刊和7种最高影响因子重症医学期刊的94项ARDS/ALI或脓毒症个体随机对照试验,排除整群随机试验,由两名独立评价者提取数据,对入组率(按时间、按中心)进行随机效应Meta分析。总体平均入组率为每中心每月0.83例(95%CI 0.57-1.21),ARDS/ALI试验为0.48(95%CI 0.32-0.70),脓毒症试验为0.98(95%CI 0.62-1.56);单中心试验入组率4.86(95%CI 2.49-9.51)显著高于多中心试验0.52(95%CI 0.41-0.66)。36项未达到目标样本量95%的试验中,8项(22%)报告入组缓慢为原因。作者认为需要新方法提高重症试验入组效率。
要点
- 94项ARDS/ALI与脓毒症随机对照试验总体平均入组率为每中心每月0.83例(95%CI 0.57-1.21)。
- ARDS/ALI试验入组率为每中心每月0.48例(95%CI 0.32-0.70),脓毒症试验为0.98例(95%CI 0.62-1.56)。
- 单中心试验入组率4.86例/中心/月(95%CI 2.49-9.51)显著高于多中心试验0.52例/中心/月(95%CI 0.41-0.66)。
- 53%的试验评价药物干预,78%为非企业资助,81%要求前瞻性知情同意。
- 36项入组未达目标样本量95%的试验中,8项(22%)报告入组缓慢为原因。
适用人群与场景
- 2009至2019年间发表于7种最高影响因子综合医学期刊和7种最高影响因子重症医学期刊的ARDS、ALI或脓毒症个体随机对照试验;排除整群随机试验。
研究设计与关键结果
- 研究类型:系统评价与随机效应Meta分析;检索Pubmed,最终纳入94项随机对照试验。
- 试验特征:53%评价药物干预,78%为非企业资助,81%要求前瞻性知情同意。
- 主要结局:总体平均入组率为每中心每月0.83例(95%CI 0.57-1.21)。
- 亚组:ARDS/ALI试验入组率0.48例/中心/月(95%CI 0.32-0.70),脓毒症试验0.98例/中心/月(95%CI 0.62-1.56)。
- 单中心试验入组率4.86例/中心/月(95%CI 2.49-9.51)显著高于多中心试验0.52例/中心/月(95%CI 0.41-0.66)。
- 36项入组未达目标样本量95%的试验中,8项(22%)报告入组缓慢为原因。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(纳入94项随机对照试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要新方法提高重症试验入组效率,以促进最佳证据转化为实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Enrollment problems are common among randomized controlled trials conducted in the ICU. However, little is known about actual trial enrollment rates and influential factors. We set out to determine the overall enrollment rate in recent randomized controlled trials (RCTs) of patients with acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or sepsis, and which factors influenced enrollment rate.
METHODS: We conducted a systematic review by searching Pubmed using predefined terms for ARDS/ALI and sepsis to identify individually RCTs published among the seven highest impact general medicine and seven highest impact critical care journals between 2009 and 2019. Cluster randomized trials were excluded. Data were extracted by two independent reviewers using an electronic database management system. We conducted a random-effects meta-analysis of the eligible trials for the primary outcome of enrollment rate by time and site.
RESULTS: Out of 457 articles identified, 94 trials met inclusion criteria. Trials most commonly evaluated pharmaceutical interventions (53%), were non-industry funded (78%), and required prospective informed consent (81%). The overall mean enrollment rate was 0.83 (95% confidence interval: 0.57-1.21) participants per month per site. Enrollment in ARDS/ALI and sepsis trials were 0.48 (95% CI 0.32-0.70) and 0.98 (95% CI 0.62-1.56) respectively. The enrollment rate was significantly higher for single-center trials (4.86; 95% CI 2.49-9.51) than multicenter trials (0.52; 95% CI 0.41-0.66). Of the 36 trials that enrolled < 95% of the target sample size, 8 (22%) reported slow enrollment as the reason.
CONCLUSIONS: In this systematic review and meta-analysis, recent ARDS/ALI and sepsis clinical trials had an overall enrollment rate of less than 1 participant per site per month. Novel approaches to improve critical care trial enrollment efficiency are needed to facilitate the translation of best evidence into practice.
参考来源
- Krutsinger DC, Yadav KN, Harhay MO, et al. A systematic review and meta-analysis of enrollment into ARDS and sepsis trials published between 2009 and 2019 in major journals. Crit Care. 2021. PMID: 34781998. doi:10.1186/s13054-021-03804-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。